A phase I clinical trial assessed the efficacy of a peptide vaccination with RHAMM R3 in patients with AML, myelodysplastic syndrome (MDS), and multiple myeloma and showed in 7 out of 10 patients an increase of RHAMM R3-specific effector T cells with three patients achieving clinical responses [131]. This evidence concerns the gene HMMR and myelodysplastic syndrome.